(34.0%) had an available baseline PZA DST result, 612 (73.6%) of whom were PZA-resistant. We found no association between treatment success and PZA susceptibility (adjusted odds ratio [aOR] 0.86, 95%CI 0.51-1.44, P ¼ 0.6) in patients treated with PZA. Furthermore, among patients with no baseline PZA DST result, no evidence was seen of an association between treatment success and PZA treatment duration (aOR 0.86, 95%CI 0.49-1.51, P ¼ 0.6). [INH] , the two main drugs used to treat drug-susceptible TB) in 23% of new cases and 62% of retreatment cases. 1 In Karakalpakstan, a semi-autonomous republic in Uzbekistan, pyrazinamide (PZA) resistance has been reported in 63% of MDR-TB cases. 2 A recent metaanalysis estimated that 61% of patients with MDR-TB worldwide had PZA resistance, which equates to 270 000 cases annually. 3 The World Health Organization (WHO) recommendation is to include PZA in an MDR-TB regimen unless evidence of resistance exists. 4 PZA acts predominantly as a sterilising agent on semi-dormant mycobacteria, 5 and reduces the required treatment duration in drug-susceptible TB. 6 The main therapeutic effect in drug-susceptible TB occurs during the first 2 months of treatment, 6 but whether the same is applicable for MDR-TB is not known. 4, [6] [7] [8] PZA has shown synergistic effects with other anti-tuberculosis drugs, [9] [10] [11] which has resulted in its retention in the shorter WHO-recommended MDR-TB regimen, as well as in several novel regimens under evaluation. 4, [12] [13] [14] [15] Difficulties exist with PZA drug susceptibility testing (DST) using the standard phenotypic method of the BACTECe MGITe (Mycobacteria Growth Indicator Tube) 960 System, as reports have often shown uncertain reproducibility and reliability, with testing prone to false resistance results. [16] [17] [18] A major factor influencing the WHO recommendation is a recent meta-analysis showing an association between successful outcomes and PZA susceptibility among MDR-TB patients treated with PZA-containing regimens. 19 Three small primary studies that assessed the association of PZA resistance with treatment outcomes showed conflicting results. [20] [21] [22] No larger primary study is available, and routine PZA DST was not an inclusion criterion in the meta-analysis. 19 The primary aim of the present study was to assess the effect of PZA susceptibility on treatment outcome among MDR-TB patients treated with an intensivephase regimen containing PZA within the drugresistant TB (DR-TB) programme in Karakalpakstan, Uzbekistan. We hypothesised that treatment outcomes would be better in PZA-susceptible than PZAresistant disease. We further assessed the effect of PZA treatment duration on outcomes among patients with PZA strains of unknown resistance or PZAresistant strains. 
STUDY POPULATION AND METHODS

Definitions
We calculated the number of (non-PZA) drugs to which the strain was resistant at diagnosis as the sum of resistance to INH, RMP, ethambutol (EMB), streptomycin (SM), ofloxacin (OFX), kanamycin (KM) and capreomycin (CPM). If DST results against a drug were unavailable, the strain was assumed to have unknown resistance to the drug in question.
Patients with MDR-TB strains were either known to be susceptible or had unknown DST results against the second-line drugs (SLDs) OFX, KM and CPM. Pre-XDR-TB strains had confirmed resistance to either OFX or both KM and CPM. XDR-TB strains had confirmed resistance to OFX and at least one of KM and CPM. Potentially effective drugs, excluding PZA, were each counted as 1 if DST showed susceptibility or was not performed (see Appendix). Acquired resistance from follow-up DST was taken into account in the monthly calculations; the median in the intensive phase was also estimated. DST for RMP, INH, EMB, OFX, KM, CPM, and SM was included. DST for ethionamide, para-aminosalicylic acid and cycloserine was not considered due to reports of unreliable results; 27 universal susceptibility to these agents was an inherent assumption. OFX-resistant specimens were also considered resistant to levofloxacin and moxifloxacin (MFX), as neither of these were tested. KM-resistant specimens were considered CPM-susceptible if CPM DST showed susceptibility or was unknown, and vice versa. We calculated PZA treatment through days of prescribed PZA.
We defined PZA treatment as a full PZA-containing intensive phase as PZA treatment on 780% of days during the intensive phase, a partial PZA regimen as ,80% of days in the intensive phase, an incomplete PZA regimen as 716% but ,80% of days in the intensive phase, and no PZA treatment as ,16% of days in the intensive phase (equivalent to ,30 days in a 6-month intensive phase). All outcomes were based on the WHO 2013 definitions. 26 A 6month cut-off was used until the outcome 'failure due to culture conversion and culture reversion' could be declared, as this was the defined intensive phase; 'failure due to acquired resistance' could be declared at any time. 26 'Death' and 'loss to follow-up (LTFU)' were defined according to programme decisions, unless a patient had been defined as 'failure' earlier during treatment.
Data management and analysis
We used a retrospective cohort study design and multivariable logistic regression. The primary analysis in patients receiving a full PZA-containing intensive phase with known PZA DST results was used to calculate the odds ratio (OR) of a successful outcome (cure or treatment completed) for PZA susceptibility compared with resistance. A successful outcome was compared with unsuccessful outcomes (failure or death). We decided a priori to include the variables sex, age, previous use of first-line drugs (FLDs) RMP, INH, EMB, PZA and SM, and presence of cavities on chest X-ray, which are commonly associated with treatment outcome and are adjusted for in other studies. 19, 22, 28 We also included year of treatment initiation to account for unmeasured timedependent effects. The secondary analysis assessed the association between successful outcome and duration of PZA treatment, first among patients without diagnostic PZA DST results and then among patients with PZA resistance. We restricted the analysis to patients with no PZA DST results to reduce bias, 29 as a PZA DST result could guide clinical decisions. The same analyses could not be performed in patients with PZA susceptibility at diagnosis due to low numbers.
In the descriptive analysis, we used the v 2 test for statistical testing for categorical variables and the Wilcoxon rank-sum test for continuous variables. We used the Wald test in the crude and multivariable models, and the likelihood ratio test to assess interaction in the final multivariable logistic models. Missing values were included as unknown if .10% were missing, but were otherwise coded as missing. Data cleaning and analysis were performed using STATA v14.1 (Stata Corporation, College Station, TX, USA).
Power calculations for the main analysis using the available patient cohort (n ¼ 508, outcomes ratio 3.5 [successful 396; death/failure 112], baseline proportion of success 78%) used an OR of 1.6 for successful outcome in PZA-susceptible compared with PZAresistant MDR-TB based on a meta-analysis, 19 with a two-sided likelihood ratio test and a ¼ 0.05, yielding a power of 40%.
Sensitivity analyses were undertaken for the primary analysis in patients with only bacteriologically confirmed TB, receiving 76 months of treatment, and only under the 2012 programme. An additional model compared treatment success with death/failure/LTFU.
The study fulfilled the exemption criteria of the MSF Ethics Review Board (ERB) for a posteriori analyses of routinely collected clinical data, and did not require MSF ERB review. 30 The study was conducted with permission from Dr S Wong (Medical Director, MSF, Operational Centre Amsterdam, The Netherlands). The study protocol was also approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, London, UK.
RESULTS
Patient characteristics
Of a total of 2593 patients, 2446 (94.3%) were included, 832 (34.0%) of whom had a diagnostic PZA DST result available (Appendix Figure) . Table  1 shows the characteristics of the 2446 patients included. The median treatment duration was 20 months (range 0-38), and the median duration of PZA treatment was 12 months (range 0-34). Isolates were resistant to a median of four drugs at diagnosis (interquartile range 4-4); 87.2% (n ¼ 2132) of the intensive phase regimens contained at least five effective drugs. A successful outcome was recorded in 59.4% of patients, 5.8% died, 11.9% failed treatment and 22.9% were lost to follow-up. A full PZA regimen was prescribed in 90.1% (1450/ 1610) of patients with no available PZA DST result, 90.8% (197/217) of those with PZA-susceptible strains and 76.6% (469/612) of those with PZAresistant strains (seven patients were excluded as they had received PZA treatment only in the continuation phase). Of patients with available PZA DST results at diagnosis, 73.6% (612/832) had PZA-resistant strains.
Main results
In the primary unadjusted analysis ( Table 2) , we found no evidence of an association between a successful outcome and PZA susceptibility among patients receiving a full PZA-containing intensive phase (odds ratio [OR] 1.04, 95% confidence interval [CI] 0.65-1.65, P ¼ 0.9). Patients with previous use of FLDs (OR 0.54, 95%CI 0.31-0.93, P ¼ 0.03) and SLDs (OR 0.55, 95%CI 0.32-0.95, P ¼ 0.03) had approximately 45% lower odds of success. The odds of a successful outcome decreased with increasing numbers of drugs to which the strain was resistant at diagnosis (OR 0.64, 95%CI 0.51-0.81 per resistant drug, P , 0.001).
In the multivariable analysis (Table 2) , there was also no evidence of an association between a successful outcome and PZA susceptibility (OR 0.86, 95%CI 0.51-1.44, P ¼ 0.6), after adjustment for sex, age, previous FLD use, cavities on chest X-ray at diagnosis, programme year and number of drugs to which the diagnostic strain was resistant. We found no clinically important interaction variables in the final model. Sputum smear and previous use of SLDs did not change the OR by more than 10% in the multivariable model, and were not included in the final analysis. The model comparing success with death/failure/LTFU had comparable results (Appendix Table A .2). Similar results were seen in the three sensitivity analyses (Appendix Tables A.3 
-A.5).
The secondary adjusted multivariable analyses showed no evidence of an association between successful outcome and a full PZA-containing intensive phase, either in patients with no available baseline PZA DST results at diagnosis (OR 0.86, 95%CI 0.49-1.51, P ¼ 0.6; Appendix 
DISCUSSION
This is the largest single-site study to assess the impact of PZA resistance and treatment duration on treatment outcome in patients with MDR-TB. We found no evidence of an association between a successful outcome and PZA susceptibility among MDR-TB patients treated with a standard full PZA-containing intensive phase of a WHO-recommended regimen in a high MDR-TB burden setting. There was no evidence of an association between a successful outcome and PZA treatment duration in the intensive phase.
The main result was unexpected, and did not support our hypothesis that a treatment regimen with a full PZA-containing intensive phase would improve treatment outcomes in patients with PZA-susceptible strains compared with PZA-resistant strains. Our results are therefore consistent with two smaller previous primary studies, 20, 21 but not with the metaanalysis and another small primary study from Peru. 19, 31 Several explanations could be postulated. Even with the inclusion of all eligible patients for more than one decade, the sample size had low power for the main analysis. The retrospective and observational nature of the study contributed to an increased risk of bias. Prescription of a full PZA-containing intensive phase could also have been influenced by PZA DST results or other associated baseline characteristics, resulting in selection bias, although clear protocols were in use to routinely include PZA in MDR-TB regimens.
The main effect of PZA may be its contribution to shortening the duration of treatment, 32, 33 rather than improving the outcome of an already lengthy regimen. This would also support the improved result of the shortened treatment regimen now recommended by the WHO that includes PZA. 4 Patients might also have had sufficient likely effective drugs in their regimen (87.2% had five or more likely effective drugs in the intensive phase; Table 1 ), rendering additional PZA redundant. 22 The secondary analysis also showed insufficient evidence of an association between a successful outcome and a full PZA-containing intensive phase among patients with unknown PZA DST results and those with PZA-resistant MDR-TB strains. A possible explanation in the former could be the high background PZA resistance in MDR-TB patients in Karakalpakstan (73.6%; Table 1 ). Optimal PZA treatment duration in MDR-TB may be longer than the 2 months used for drug-susceptible TB 6 due to the lower efficacy of SLDs. This effect could be limited to patients with PZA-susceptible MDR-TB strains, but PZA-resistant strains might also benefit, due to a synergistic effect with other drugs. 34 We did not find that a different duration of PZA treatment in the intensive phase was associated with greater odds of a successful outcome, although some numbers were small (Appendix Table A .6) .
The generalisability of this study would be limited to settings with low HIV prevalence and high background prevalence of SLD resistance, as in other former Soviet Union countries. Caution is needed when extrapolating the results to other settings, as background resistance patterns might be expected to change the impact of PZA treatment. Furthermore, these results refer to a background standard MDR-TB regimen, but might not be applicable to newer regimens.
The main limitation of our study was the low power for the main analysis and the risk of bias due to the observational study design. Although we used both restriction and stratification, bias cannot be accounted for in the analysis. Patients were included over a long time, and unmeasured factors could lead to residual confounding, although we adjusted for programme year. Another limitation was the determination of PZA susceptibility using MGIT, with possible false resistance, which could have affected the results. Furthermore, adjustment was made for initial PZA DST results, but not for acquired PZA resistance during treatment. Another limitation was the way in which potentially effective drugs were all counted as 1; we were unable to justify the assignment of differential weights.
Nevertheless, because this was the first large primary study with these findings, with all the associated limitations of a retrospective observational cohort, cautious consideration should be made before changing treatment protocols. A clinical trial assessing the effect of PZA inclusion and treatment duration could address this question, but might not be regarded as a priority in the current arena. An updated meta-analysis including this full cohort would be worthwhile.
CONCLUSIONS
The present study provided provocative but insufficient evidence to warrant changing PZA treatment protocols, although the evidence relating to PZA for the WHO 2016 guidelines was weak. Until further evidence supporting these findings emerges, it seems prudent to continue including PZA in standard MDR-TB regimens unless resistance is certain.
APPENDIX
Drug groups for the treatment of multidrug-resistant tuberculosis according to World Health Organization 2016 guidelines. 26 Group A: Levofloxacin, moxifloxacin, gatifloxacin Group B: Amikacin, kanamycin, capreomycin (streptomycin)
Group C: Ethionamide/prothionamide, cycloserine/ terizidone, linezolid, clofazimine Group D: D1: Pyrazinamide, ethambutol, high-dose isoniazid D2: Bedaquiline, delamanid D3: Para-aminosalicylic acid, imipenem-cilastin, meropenem, amoxicillin-clavulanate, thioacetazone. 
